Discover Vor BiopharmaVor Biopharma Inc.'s potential with telitacicept amid funding challenges and market risks. Click for ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without ...
DelveInsight’s “Marginal Zone Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It ...
Dermatologists long reluctant to tackle cutaneous lupus erythematosus may be more open to treating patients with approvals ...
BGB-11417-202 ( NCT05479994) is an open-label, phase 2, and a potential registrational study evaluating the efficacy and safety of sonrotoclax in 100 heavily pretreated patients with R/R CLL/SLL. At a ...
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune ...
Turkey: A recent study published in Surgery Today highlights a potential link between periodontitis, a chronic oral disease, ...
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep ...
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) -- Of the ...
Roswell Park scientists show that IL-36γ–armored CAR T cells reprogram neutrophils to trigger powerful immune responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback